Grant Yonehiro - 24 Oct 2025 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Reporting relationship: Chief Operating Officer
Issuer ticker: BOLT
Reported as of: 24 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Oct 2025, 19:18:58 UTC
Prior SEC filing: 05 May 2025
Next SEC filing: 16 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ William P. Quinn, Attorney-in-Fact

Key filing fact

Grant Yonehiro filed Form 4 for Bolt Biotherapeutics, Inc. (BOLT) on 24 Oct 2025.

Key facts

This page summarizes Grant Yonehiro's Form 4 filing for Bolt Biotherapeutics, Inc. (BOLT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Oct 2025, 19:18.

Change

Previous filing in this sequence was filed on 05 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001428666 Primary reporting owner

Yonehiro Grant

Relationship: Chief Operating Officer
Address: C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY
Signature: /s/ William P. Quinn, Attorney-in-Fact
Signature date: 24 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BOLT transaction

Common Stock

Award

Transaction value: $0
Shares: +30,000
Change %: +336%
Price: $0.000000
Shares after: 38,918
Date: 22 Oct 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.

Footnote F2

The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.